식이유도 비만 흰쥐에서 루와이 위우회술이 체중, 그렐린 및 PYY<SUB>3-36</SUB>에 미치는 영향

다국어 초록 (Multilingual Abstract)

Purpose: Obesity is considered an epidemic worldwide. Nonsurgical treatment such as dietary, physical and pharmacological therapies have limited success and thus, bariatric surgery is the ultimate option. Roux-en-Y gastric bypass (RYGB) is a bariatric procedure, which is a restrictive and malabsorptive procedure simultaneously. The purpose of this study was to develop surgical rat models of bariatric surgery and analyze the effect of gastric bypass on body weight, ghrelin and polypeptide YY3-36 (PYY3-36) changes in rats.
Methods: RYGB, sleeve gastrectomy (SG) and sham operation were performed in diet-induced obese rats and compared to obese control and normal control rats.
Results: In RYGB group, 20.7±8.56% of weight loss was achieved on postoperative day 18 and maintained thereafter. This outcome was significant compared to SG (8.8±1.82%) and sham operated (6.2±2.45%) groups. When pre- and postoperative ghrelin levels were compared, there was a significant decrease in RYGB group (P＜0.028); nonetheless, there was no difference in SG and sham operated groups. When pre- and postoperative PYY3-36 levels were compared, there was a significant increase in RYGB (P＜0.028), SG (P＜0.031) and sham operated (P＜0.031) groups.
Conclusion: We developed surgical rat models of RYGB and SG. Those rats that underwent RYGB lost significant body weight and maintained the weight thereafter. The decrease in ghrelin and increase in PYY3-36 may be associated with loss of appetite and delay in intestinal transit time with subsequent weight loss maintenance. In the future, this rat model would serve as a tool for further study on endocrine regulation of obesity.

목차 (Table of Contents)

• 서론
• 방법
• 결과
• 고찰
• 결론
• REFERENCES

참고문헌 (Reference)

1 Pories WJ, "Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus" 222 : 339-350, 1995

2 Korner J, "To eat or not to eat - how the gut talks to the brain" 349 : 926-928, 2003

3 Gnanapavan S, "The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans" 87 : 2988-, 2002

4 National Institutes of Health, "The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults"

5 Ariyasu H, "Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans" 86 : 4753-4758, 2001

6 Cummings DE, "Roles for ghrelin in the regulation of appetite and body weight" 138 : 389-396, 2003

7 Cummings DE, "Roles for ghrelin in the regulation of appetite and body weight" 138 : 389-396, 2003

8 Cummings DE, "Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery" 346 : 1623-1630, 2002

9 Ballantyne GH, "Peptide YY(1-36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery" 16 : 795-803, 2006

10 Ballantyne GH, "Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions" 16 : 651-658, 2006

11 Schirmer B, "Morbid obesity. In Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 17th ed." Elsevier Saunders 357-399, 2004

12 Horvath TL, "Minireview: ghrelin and the regulation of energy balance--a hypothalamic perspective" 142 : 4163-4169, 2001

13 Zigman JM, "Minireview: From anorexia to obesity--the yin and yang of body weight control" 144 : 3749-3756, 2003

14 Shin AC, "Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery" 151 : 1588-1597, 2010

15 Batterham RL, "Inhibition of food intake in obese subjects by peptide YY3-36" 349 : 941-948, 2003

16 le Roux CW, "Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters" 243 : 108-114, 2006

17 Asakawa A, "Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin" 120 : 337-345, 2001

18 Kojima M, "Ghrelin is a growth-hormone-releasing acylated peptide from stomach" 402 : 656-660, 1999

19 Wren AM, "Ghrelin causes hyperphagia and obesity in rats" 50 : 2540-2547, 2001

20 Holdstock C, "Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans" 88 : 3177-3183, 2003

21 "Gastrointestinal surgery for severe obesity. Proceedings of a National Institutes of Health Consensus Development Conference. March 25-27, 1991, Bethesda, MD" 55 : 487S-619S, 1992

22 Xu Y, "Gastric bypass model in the obese rat to study metabolic mechanisms of weight loss" 107 : 56-63, 2002

23 Stylopoulos N, "Changes in serum ghrelin predict weight loss after Roux-en-Y gastric bypass in rats" 19 : 942-946, 2005

24 Beckman LM, "Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review" 110 : 571-584, 2010

25 Suzuki S, "Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model" 138 : 283-290, 2005

26 Meguid MM, "A surgical rat model of human Roux-en-Y gastric bypass" 8 : 621-630, 2004

27 Nakazato M, "A role for ghrelin in the central regulation of feeding" 409 : 194-198, 2001